Duloxetine and cognitive behavioral therapy with phone-based support for the treatment of chronic musculoskeletal pain: study protocol of the PRECICE randomized control trial.
Duloxetine Hydrochloride
/ therapeutic use
Humans
Cognitive Behavioral Therapy
/ methods
Chronic Pain
/ therapy
Musculoskeletal Pain
/ therapy
Randomized Controlled Trials as Topic
Treatment Outcome
Combined Modality Therapy
Pain Measurement
Telephone
Motivational Interviewing
Analgesics
/ therapeutic use
Time Factors
Internet-Based Intervention
Pain Management
/ methods
Adaptation, Psychological
Adult
Chronic musculoskeletal pain
Cognitive behavioral therapy
Duloxetine
Motivational interviewing
Randomized controlled trial
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
18 May 2024
18 May 2024
Historique:
received:
02
02
2024
accepted:
07
05
2024
medline:
19
5
2024
pubmed:
19
5
2024
entrez:
18
5
2024
Statut:
epublish
Résumé
Chronic musculoskeletal pain (CMP) is the most common, disabling, and costly of all pain conditions. While evidence exists for the efficacy of both duloxetine and web-based cognitive behavioral therapy (CBT) as monotherapy, there is a clear need to consider study of treatment components that may complement each other. In addition, given the reported association between patient's adherence and treatment outcomes, strategies are needed to enhance participant's motivation to adopt and maintain continued use of newly learned pain coping skills from CBT. Two hundred eighty participants will be recruited from the primary care clinics of a large academic health care system in North Carolina. Participants with CMP will be randomized to one of three treatment arms: (1) combination treatment (duloxetine + web-based self-guided CBT) with phone-based motivational interviewing (MI), (2) combination treatment without phone-based MI, and (3) duloxetine monotherapy. Participants will be in the study for 24 weeks and will be assessed at baseline, week 13, and week 25. The primary outcome is the Brief Pain Inventory (BPI)-Global Pain Severity score, which combines BPI pain severity and BPI pain interference. Secondary measures include between-group comparisons in mean BPI pain severity and BPI pain interference scores. Data collection and outcome assessment will be blinded to treatment group assignment. This randomized controlled trial (RCT) will determine if combination treatment with duloxetine and web-based CBT is superior to duloxetine monotherapy for the management of CMP. Furthermore, this RCT will determine the effectiveness of phone-based motivational interviewing in promoting the continued practice of pain coping skills, thereby enhancing treatment outcomes. NCT04395001 ClinicalTrials.gov. Registered on May 15, 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic musculoskeletal pain (CMP) is the most common, disabling, and costly of all pain conditions. While evidence exists for the efficacy of both duloxetine and web-based cognitive behavioral therapy (CBT) as monotherapy, there is a clear need to consider study of treatment components that may complement each other. In addition, given the reported association between patient's adherence and treatment outcomes, strategies are needed to enhance participant's motivation to adopt and maintain continued use of newly learned pain coping skills from CBT.
METHODS
METHODS
Two hundred eighty participants will be recruited from the primary care clinics of a large academic health care system in North Carolina. Participants with CMP will be randomized to one of three treatment arms: (1) combination treatment (duloxetine + web-based self-guided CBT) with phone-based motivational interviewing (MI), (2) combination treatment without phone-based MI, and (3) duloxetine monotherapy. Participants will be in the study for 24 weeks and will be assessed at baseline, week 13, and week 25. The primary outcome is the Brief Pain Inventory (BPI)-Global Pain Severity score, which combines BPI pain severity and BPI pain interference. Secondary measures include between-group comparisons in mean BPI pain severity and BPI pain interference scores. Data collection and outcome assessment will be blinded to treatment group assignment.
DISCUSSION
CONCLUSIONS
This randomized controlled trial (RCT) will determine if combination treatment with duloxetine and web-based CBT is superior to duloxetine monotherapy for the management of CMP. Furthermore, this RCT will determine the effectiveness of phone-based motivational interviewing in promoting the continued practice of pain coping skills, thereby enhancing treatment outcomes.
TRIAL REGISTRATION
BACKGROUND
NCT04395001 ClinicalTrials.gov. Registered on May 15, 2020.
Identifiants
pubmed: 38762720
doi: 10.1186/s13063-024-08158-x
pii: 10.1186/s13063-024-08158-x
doi:
Banques de données
ClinicalTrials.gov
['NCT04395001']
Types de publication
Journal Article
Clinical Trial Protocol
Langues
eng
Sous-ensembles de citation
IM
Pagination
330Subventions
Organisme : NINR NIH HHS
ID : 1UG3NR019196-01
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res. 2003;12(1):34–43.
pubmed: 12830308
doi: 10.1002/mpr.140
Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715–24.
pubmed: 22607834
doi: 10.1016/j.jpain.2012.03.009
Magni G, Marchetti M, Moreschi C, Merskey H, Luchini SR. Chronic musculoskeletal pain and depressive symptoms in the National Health and Nutrition Examination. I Epidemiologic follow-up study Pain. 1993;53(2):163–8.
pubmed: 8336986
National Research Council, Institute of Medicine. Musculoskeletal disorders and the workplace: low back and upper extremities. 1st ed. Washington, D.C.: National Academies Press; 2001.
Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canada–prevalence, treatment, impact and the role of opioid analgesia. Pain Res Manag. 2002;7(4):179–84.
pubmed: 12518174
doi: 10.1155/2002/323085
Burckhardt CS, Clark SR, Bennett RM. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol. 1993;20(3):475–9.
pubmed: 8478854
Hill CL, Parsons J, Taylor A, Leach G. Health related quality of life in a population sample with arthritis. J Rheumatol. 1999;26(9):2029–35.
pubmed: 10493687
Ang DC, Kroenke K. Depression in Osteoarthritis. In: Brandt KD, Doherty M, Lohmander S, editors. Osteoarthritis. 2nd ed. United Kingdom: Oxford University Press; 2003. p. 331–8.
Curatolo M, Bogduk N. Pharmacologic pain treatment of musculoskeletal disorders: current perspectives and future prospects. Clin J Pain. 2001;17(1):25–32.
pubmed: 11289086
doi: 10.1097/00002508-200103000-00005
Von Korff MR. Long-term use of opioids for complex chronic pain. Best Pract Res Clin Rheumatol. 2013;27(5):663–72.
doi: 10.1016/j.berh.2013.09.011
Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589–94.
pubmed: 16717269
pmcid: 1459894
doi: 10.1503/cmaj.051528
Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146(2):116–27.
pubmed: 17227935
doi: 10.7326/0003-4819-146-2-200701160-00006
Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006;125(1–2):172–9.
pubmed: 16842922
doi: 10.1016/j.pain.2006.06.009
Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet. 1996;347(8995):143–7.
pubmed: 8544547
doi: 10.1016/S0140-6736(96)90339-6
Bove SE, Flatters SJ, Inglis JJ, Mantyh PW. New advances in musculoskeletal pain. Brain Res Rev. 2009;60(1):187–201.
pubmed: 19166876
doi: 10.1016/j.brainresrev.2008.12.012
Staud R. Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions. Expert Rev Neurother. 2012;12(5):577–85.
pubmed: 22550986
pmcid: 3373184
doi: 10.1586/ern.12.41
Muraki S, Oka H, Akune T, Mabuchi A, En-Yo Y, Yoshida M, et al. Prevalence of radiographic lumbar spondylosis and its association with low back pain in elderly subjects of population-based cohorts: the ROAD study. Ann Rheum Dis. 2009;68(9):1401–6.
pubmed: 18718988
doi: 10.1136/ard.2007.087296
Siddall PJ, Cousins MJ. Persistent pain as a disease entity: implications for clinical management. Anesth Analg. 2004;99(2):510–20.
pubmed: 15271732
doi: 10.1213/01.ANE.0000133383.17666.3A
Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron. 2007;55(3):377–91.
pubmed: 17678852
doi: 10.1016/j.neuron.2007.07.012
Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain. 1997;13(3):189–96.
pubmed: 9303250
doi: 10.1097/00002508-199709000-00003
Arendt-Nielsen L, Graven-Nielsen T. Central sensitization in fibromyalgia and other musculoskeletal disorders. Curr Pain Headache Rep. 2003;7(5):355–61.
pubmed: 12946288
doi: 10.1007/s11916-003-0034-0
Bajaj P, Bajaj P, Graven-Nielsen T, Arendt-Nielsen L. Osteoarthritis and its association with muscle hyperalgesia: an experimental controlled study. Pain. 2001;93(2):107–14.
pubmed: 11427321
doi: 10.1016/S0304-3959(01)00300-1
Neziri AY, Haesler S, Petersen-Felix S, Muller M, Arendt-Nielsen L, Manresa JB, et al. Generalized expansion of nociceptive reflex receptive fields in chronic pain patients. Pain. 2010;151(3):798–805.
pubmed: 20926191
doi: 10.1016/j.pain.2010.09.017
O’Neill S, Manniche C, Graven-Nielsen T, Arendt-Nielsen L. Generalized deep-tissue hyperalgesia in patients with chronic low-back pain. Eur J Pain. 2007;11(4):415–20.
pubmed: 16815054
doi: 10.1016/j.ejpain.2006.05.009
Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2–15.
pubmed: 20961685
doi: 10.1016/j.pain.2010.09.030
Bardin L, Gregoire S, Aliaga M, Malfetes N, Vitton O, Ladure P, et al. Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. Neurosci Res. 2010;66(2):135–40.
pubmed: 19883699
doi: 10.1016/j.neures.2009.10.009
Munro G. Pharmacological assessment of the rat formalin test utilizing the clinically used analgesic drugs gabapentin, lamotrigine, morphine, duloxetine, tramadol and ibuprofen: influence of low and high formalin concentrations. Eur J Pharmacol. 2009;605(1–3):95–102.
pubmed: 19168051
doi: 10.1016/j.ejphar.2009.01.004
Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11(6):505–21.
pubmed: 20418173
doi: 10.1016/j.jpain.2010.01.002
Pergolizzi JV, Raffa RB, Taylor R, Rodriguez G, Nalamachu S, Langley P. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract. 2013;13(3):239–52.
pubmed: 22716295
doi: 10.1111/j.1533-2500.2012.00578.x
Ma X, Zhou S, Sun W, Sun J, Li G, Wang L, Guo Y. Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2023;24(1):394.
pubmed: 37198620
pmcid: 10193733
doi: 10.1186/s12891-023-06488-6
Robinson RL, Kroenke K, Williams DA, Mease P, Chen Y, Faries D, et al. Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the reflections study. Pain Med. 2013;14(9):1400–15.
pubmed: 23758985
doi: 10.1111/pme.12168
Cawston H, Davie A, Paget MA, Skljarevski V, Happich M. Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain. Eur Spine J. 2013;22(9):1996–2009.
pubmed: 23686477
pmcid: 3777076
doi: 10.1007/s00586-013-2804-7
Williams ACdC, Fisher E, Hearn L, Eccleston C. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev. 2020;8(8):CD007407.
Ang DC, Chakr R, Mazzuca S, France CR, Steiner J, Stump T. Cognitive-behavioral therapy attenuates nociceptive responding in patients with fibromyalgia: a pilot study. Arthritis Care Res (Hoboken). 2010;62(5):618–23.
pubmed: 20191481
doi: 10.1002/acr.20119
Rini C, Williams DA, Broderick JE, Keefe FJ. Meeting them where they are: using the Internet to deliver behavioral medicine interventions for pain. Transl Behav Med. 2012;2(1):82–92.
pubmed: 22924084
pmcid: 3423892
doi: 10.1007/s13142-011-0107-2
Buhrman M, Gordh T, Andersson G. Internet interventions for chronic pain including headache: a systematic review. Internet Interv. 2016;4:17–34.
pubmed: 30135787
pmcid: 6096254
doi: 10.1016/j.invent.2015.12.001
Macea DD, Gajos K, Daglia Calil YA, Fregni F. The efficacy of Web-based cognitive behavioral interventions for chronic pain: a systematic review and meta-analysis. J Pain. 2010;11(10):917–29.
pubmed: 20650691
doi: 10.1016/j.jpain.2010.06.005
Barnes RD, Ivezaj V. A systematic review of motivational interviewing for weight loss among adults in primary care. Obes Rev. 2015;16(4):304–18.
pubmed: 25752449
pmcid: 4491487
doi: 10.1111/obr.12264
Stonerock GL, Blumenthal JA. Role of counseling to promote adherence in healthy lifestyle medicine: strategies to improve exercise adherence and enhance physical activity. Prog Cardiovasc Dis. 2017;59(5):455–62.
pubmed: 27640186
doi: 10.1016/j.pcad.2016.09.003
Jiang S, Wu L, Gao X. Beyond face-to-face individual counseling: a systematic review on alternative modes of motivational interviewing in substance abuse treatment and prevention. Addict Behav. 2017;73:216–35.
pubmed: 28554033
doi: 10.1016/j.addbeh.2017.05.023
Palacio A, Garay D, Langer B, Taylor J, Wood BA, Tamariz L. Motivational interviewing improves medication adherence: a systematic review and meta-analysis. J Gen Intern Med. 2016;31(8):929–40.
pubmed: 27160414
pmcid: 4945560
doi: 10.1007/s11606-016-3685-3
Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain. 2002;18(6):355–65.
pubmed: 12441829
doi: 10.1097/00002508-200211000-00003
Wright A, Sluka KA. Nonpharmacological treatments for musculoskeletal pain. Clin J Pain. 2001;17(1):33–46.
pubmed: 11289087
doi: 10.1097/00002508-200103000-00006
Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346: e7586.
pubmed: 23303884
pmcid: 3541470
doi: 10.1136/bmj.e7586
Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004;5(2):133–7.
pubmed: 15042521
doi: 10.1016/j.jpain.2003.12.005
Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheumatol. 2004;50(9):2974–84.
doi: 10.1002/art.20485
Dhillon S. Duloxetine: a review of its use in the management of major depressive disorder in older adults. Drugs Aging. 2013;30(1):59–79.
pubmed: 23239363
doi: 10.1007/s40266-012-0040-1
Andrade C. The safety of duloxetine during pregnancy and lactation. J Clin Psychiatry. 2014;75(12):e1423–7.
pubmed: 25551238
doi: 10.4088/JCP.14f09631
Rini C, Porter LS, Somers TJ, McKee DC, Keefe FJ. Retaining critical therapeutic elements of behavioral interventions translated for delivery via the Internet: recommendations and an example using pain coping skills training. J Med Internet Res. 2014;16(12): e245.
pubmed: 25532216
pmcid: 4285744
doi: 10.2196/jmir.3374
Bennell KL, Nelligan R, Dobson F, Rini C, Keefe F, Kasza J, et al. Effectiveness of an Internet-delivered exercise and pain-coping skills training intervention for persons with chronic knee pain: a randomized trial. Ann Intern Med. 2017;166(7):453–62.
pubmed: 28241215
doi: 10.7326/M16-1714
Ang DC, Kaleth AS, Bigatti S, Mazzuca SA, Jensen MP, Hilligoss J, et al. Research to encourage exercise for fibromyalgia (REEF): use of motivational interviewing, outcomes from a randomized-controlled trial. Clin J Pain. 2013;29(4):296–304.
pubmed: 23042474
pmcid: 3541460
doi: 10.1097/AJP.0b013e318254ac76
Moyers TB, Rowell LN, Manuel JK, Ernst D, Houck JM. The Motivational Interviewing Treatment Integrity Code (MITI 4): rationale, preliminary reliability and validity. J Subst Abuse Treat. 2016;65:36–42.
pubmed: 26874558
pmcid: 5539964
doi: 10.1016/j.jsat.2016.01.001
Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19.
pubmed: 15621359
doi: 10.1016/j.pain.2004.09.012
Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289(19):2554–9.
pubmed: 12759327
doi: 10.1001/jama.289.19.2554
Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Control Clin Trials. 1997;18(6):530–45.
pubmed: 9408716
doi: 10.1016/S0197-2456(97)00008-1
Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia. Pain Pract. 2011;11(2):120–31.
pubmed: 20642487
doi: 10.1111/j.1533-2500.2010.00403.x
Cook KF, Jensen SE, Schalet BD, Beaumont JL, Amtmann D, Czajkowski S, et al. PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions. J Clin Epidemiol. 2016;73:89–102.
pubmed: 26952842
pmcid: 5131708
doi: 10.1016/j.jclinepi.2015.08.038
HealthMeasures: Intro to PROMIS. https://www.healthmeasures.net/explore-measurement-systems/promis/intro-to-promis (2023). Accessed 17 Apr 2024.
Jensen MP, Turner JA, Romano JM, Strom SE. The Chronic Pain Coping Inventory: development and preliminary validation. Pain. 1995;60(2):203–16.
pubmed: 7784106
doi: 10.1016/0304-3959(94)00118-X
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.
pubmed: 16717171
doi: 10.1001/archinte.166.10.1092
Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317–25.
pubmed: 17339617
doi: 10.7326/0003-4819-146-5-200703060-00004
Lowe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care. 2004;42(12):1194–201.
pubmed: 15550799
doi: 10.1097/00005650-200412000-00006
Lowe B, Kroenke K, Herzog W, Grafe K. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). J Affect Disord. 2004;81(1):61–6.
pubmed: 15183601
doi: 10.1016/S0165-0327(03)00198-8
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.
pubmed: 11556941
pmcid: 1495268
doi: 10.1046/j.1525-1497.2001.016009606.x
Lowe B, Spitzer RL, Grafe K, Kroenke K, Quenter A, Zipfel S, et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses. J Affect Disord. 2004;78(2):131–40.
pubmed: 14706723
doi: 10.1016/S0165-0327(02)00237-9
Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1–3):163–73.
pubmed: 18752852
doi: 10.1016/j.jad.2008.06.026
Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286(23):2947–55.
pubmed: 11743835
doi: 10.1001/jama.286.23.2947
Kroenke K, Bair M, Damush T, Hoke S, Nicholas G, Kempf C, et al. Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP) study: design and practical implications of an intervention for comorbid pain and depression. Gen Hosp Psychiatry. 2007;29(6):506–17.
pubmed: 18022044
doi: 10.1016/j.genhosppsych.2007.08.005
Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assess. 1995;7:524–32.
doi: 10.1037/1040-3590.7.4.524
Chibnall JT, Tait RC. Confirmatory factor analysis of the Pain Catastrophizing Scale in African American and Caucasian Workers’ Compensation claimants with low back injuries. Pain. 2005;113(3):369–75.
pubmed: 15661446
doi: 10.1016/j.pain.2004.11.016
Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merrifield T, Grittmann L. The Pain Catastrophizing Scale: further psychometric evaluation with adult samples. J Behav Med. 2000;23(4):351–65.
pubmed: 10984864
doi: 10.1023/A:1005548801037
Keogh E, McCracken LM, Eccleston C. Do men and women differ in their response to interdisciplinary chronic pain management? Pain. 2005;114(1–2):37–46.
pubmed: 15733629
doi: 10.1016/j.pain.2004.12.009
Moseley GL, Nicholas MK, Hodges PW. A randomized controlled trial of intensive neurophysiology education in chronic low back pain. Clin J Pain. 2004;20(5):324–30.
pubmed: 15322439
doi: 10.1097/00002508-200409000-00007
Pit S, Byles J. Older Australians’ medication use: self-report by phone showed good agreement and accuracy compared with home visit. J Clin Epidemiol. 2010;63(4):428–34.
pubmed: 19788955
doi: 10.1016/j.jclinepi.2009.07.008
Lacasse A, Ware MA, Bourgault P, Lanctot H, Dorais M, Boulanger A, et al. Accuracy of self-reported prescribed analgesic medication use: linkage between the Quebec Pain Registry and the Quebec Administrative Prescription Claims Databases. Clin J Pain. 2016;32(2):95–102.
pubmed: 25924096
doi: 10.1097/AJP.0000000000000248
Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf. 2016;25(6):733–7.
pubmed: 26693665
doi: 10.1002/pds.3945
Kroenke K, Wu J, Yu Z, Bair MJ, Kean J, Stump T, Monahan PO. Patient Health Questionnaire Anxiety and Depression Scale: initial validation in three clinical trials. Psychosom Med. 2016;78(6):716–27.
pubmed: 27187854
pmcid: 4927366
doi: 10.1097/PSY.0000000000000322
Kroenke K, Krebs EE, Wu J, Yu Z, Chumbler NR, Bair MJ. Telecare collaborative management of chronic pain in primary care: a randomized clinical trial. JAMA. 2014;312(3):240–8.
pubmed: 25027139
doi: 10.1001/jama.2014.7689
Bushey MA, Ang D, Wu J, Outcalt SD, Krebs EE, Yu Z, Bair MJ. Multifocal pain as a predictor of pain outcomes in military veterans with chronic musculoskeletal pain: a secondary data analysis of a randomized controlled trial. Pain Med. 2021;22(7):1503–10.
pubmed: 33594404
doi: 10.1093/pm/pnaa409
Forseth KO, Forre O, Gran JT. A 5.5 year prospective study of self-reported musculoskeletal pain and of fibromyalgia in a female population: significance and natural history. Clin Rheumatol. 1999;18(2):114–21.
pubmed: 10357115
doi: 10.1007/s100670050067
Dunlop BW, LoParo D, Kinkead B, Mletzko-Crowe T, Cole SP, Nemeroff CB, et al. Benefits of sequentially adding cognitive-behavioral therapy or antidepressant medication for adults with nonremitting depression. Am J Psychiatry. 2019;176(4):275–86.
pubmed: 30764648
pmcid: 6557125
doi: 10.1176/appi.ajp.2018.18091075
Rosenzweig TM, M. TT. An update in fibromyalgia syndrome: the multimodal therapeutic approach. Am J Lifestyle Med. 2009;3(3):226–37.
Onda A, Kimura M. Reduction in anxiety during treatment with exercise and duloxetine is related to improvement of low back pain-related disability in patients with non-specific chronic low back pain. Fukushima J Med Sci. 2020;66(3):148–55.
pubmed: 33298637
pmcid: 7790464
doi: 10.5387/fms.2020-22
Kroenke K, Bair MJ, Damush TM, Wu J, Hoke S, Sutherland J, Tu W. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA. 2009;301(20):2099–110.
pubmed: 19470987
pmcid: 2884224
doi: 10.1001/jama.2009.723
Ang DC, Jensen MP, Steiner JL, Hilligoss J, Gracely RH, Saha C. Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial. Clin J Pain. 2013;29(9):747–54.
pubmed: 23446065
pmcid: 4185390
doi: 10.1097/AJP.0b013e31827a784e
Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective. Appl Health Econ Health Policy. 2013;11(3):219–36.
pubmed: 23616247
doi: 10.1007/s40258-013-0031-3
Lin CW, Haas M, Maher CG, Machado LA, van Tulder MW. Cost-effectiveness of guideline-endorsed treatments for low back pain: a systematic review. Eur Spine J. 2011;20(7):1024–38.
pubmed: 21229367
pmcid: 3176706
doi: 10.1007/s00586-010-1676-3
Gallagher RM. Biopsychosocial pain medicine and mind-brain-body science. Phys Med Rehabil Clin N Am. 2004;15(4):855–82, vii.
Wertli MM, Burgstaller JM, Weiser S, Steurer J, Kofmehl R, Held U. Influence of catastrophizing on treatment outcome in patients with nonspecific low back pain: a systematic review. Spine (Phila Pa 1976). 2014;39(3):263–73.
Edwards RR, Bingham CO 3rd, Bathon J, Haythornthwaite JA. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Rheum. 2006;55(2):325–32.
pubmed: 16583384
doi: 10.1002/art.21865
Snow-Turek LA, Norris MP, Tan G. Active and passive coping strategies in chronic pain patients. Pain. 1996;64(3):455–62.
pubmed: 8783309
doi: 10.1016/0304-3959(95)00190-5
Keefe FJ, Caldwell DS, Baucom D, Salley A, Robinson E, Timmons K, et al. Spouse-assisted coping skills training in the management of knee pain in osteoarthritis: long-term followup results. Arthritis Care Res. 1999;12(2):101–11.
pubmed: 10513498
doi: 10.1002/1529-0131(199904)12:2<101::AID-ART5>3.0.CO;2-9